AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29676237 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultramicronized palmitoylethanolamide (600 mg twice daily)
Number of subjects: 42
Study 29676237 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment except surgical therapy)
Number of subjects: 42
Study 26780107 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial hepatectomy
Number of subjects: 200
Study 26780107 — intervention group
Group type: COMPARATOR
Intervention: TACE + RFA
Number of subjects: 200
Study 25577838 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvesical single-site laparoscopic radical prostatectomy (TVSSLRP)
Number of subjects: 50
Study 25577838 — intervention group
Group type: COMPARATOR
Intervention: Nerve-sparing extraperitoneal laparoscopic radical prostatectomy (nsELRP)
Number of subjects: 50
Study 22445839 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk reduction oriented intervention (yellow light)
Number of subjects: 2120
Study 22445839 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to addiction outpatient clinic (red light)
Number of subjects: 2120
Study 22445839 — intervention group
Group type: COMPARATOR
Intervention: Consultation with school nurse or physician
Number of subjects: 2120
Study 20472498 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 50mg
Number of subjects: 13
Study 20472498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 19469746 — intervention group
Group type: EXPERIMENTAL
Intervention: PDM training (n = 366 participants)
Number of subjects: 779
Study 19469746 — intervention group
Group type: COMPARATOR
Intervention: Bupropion SR (n = 413 participants)
Number of subjects: 779
Study 15982142 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisystemic therapy (MST)
Number of subjects: 176
Study 15982142 — intervention group
Group type: COMPARATOR
Intervention: Individual therapy (IT)
Number of subjects: 176
Study 12878631 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen 50% administration during surgery and for 2 h post-surgery
Number of subjects: 100
Study 12878631 — intervention group
Group type: COMPARATOR
Intervention: Oxygen 30% administration during surgery and for 2 h post-surgery
Number of subjects: 100
Study 12878631 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen 50% administration
Number of subjects: 100
Study 12878631 — intervention group
Group type: COMPARATOR
Intervention: Oxygen 30% administration
Number of subjects: 100
Study 10388309 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 ml of contrast material (iopamidol 300 mgI/ml)
Number of subjects: 150
Study 10388309 — intervention group
Group type: COMPARATOR
Intervention: 50 ml of contrast material (iopamidol 300 mgI/ml)
Number of subjects: 150
Study 8625251 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (SMS 201.995) 500 micrograms 3 times a day
Number of subjects: 58
Study 8625251 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (SMS 201.995) 1000 micrograms 3 times a day
Number of subjects: 58
Study 8625251 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (SMS 201.995)
Number of subjects: 58
Study 30796194 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronate (10 courses of 4 mg intravenous infusions)
Number of subjects: 798
Study 29043927 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel proprietary curcumin liquid droplet micromicellar formulation (CLDM), 400 mg dose, containing 64.6 mg curcumin
Number of subjects: 12
Study 29043927 — intervention group
Group type: COMPARATOR
Intervention: 95% curcumin powder in capsule form, 400 mg dose, containing 323 mg curcumin
Number of subjects: 12
Study 27692279 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous normal saline infusion as a bolus of 22 ml/kg body weight (approximately 2 L)
Number of subjects: 15
Study 27692279 — intervention group
Group type: COMPARATOR
Intervention: Control: intravenous normal saline infusion at a minimal rate to keep the vein open
Number of subjects: 15
Study 25148841 — intervention group
Group type: EXPERIMENTAL
Intervention: Date palm pollen (DPP) administered orally (2 g daily for 42 days)
Number of subjects: 20
Study 25148841 — intervention group
Group type: COMPARATOR
Intervention: Control group (facility standard of care)
Number of subjects: 20
Study 21499177 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation
Number of subjects: 88
Study 21499177 — intervention group
Group type: COMPARATOR
Intervention: Conventional mechanical ventilation
Number of subjects: 88
Study 18416851 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive positive-pressure mechanical ventilation (NPPV)
Number of subjects: 65
Study 18416851 — intervention group
Group type: COMPARATOR
Intervention: Invasive mechanical ventilation (IMV)
Number of subjects: 65
Study 18416851 — intervention group
Group type: EXPERIMENTAL
Intervention: NPPV
Number of subjects: 65
Study 15722689 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of cholesterol levels
Number of subjects: 738
Study 15722689 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of cholesterol targets
Number of subjects: 738
Study 15722689 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge among specific demographics
Number of subjects: 738
Study 15722689 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge among patients with risk factors
Number of subjects: 738
Study 12764232 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with acute cerebral ischemia
Number of subjects: 92
Study 10815850 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental bicarbonate solution
Number of subjects: 10
Study 10815850 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 10
Study 8751396 — intervention group
Group type: EXPERIMENTAL
Intervention: Conformal neutron/photon irradiation (9-10 Neutron + 38 Photon Gy)
Number of subjects: 76
Study 8751396 — intervention group
Group type: EXPERIMENTAL
Intervention: Conformal neutron/photon irradiation with neoadjuvant hormonal therapy
Number of subjects: 76
Study 8751396 — intervention group
Group type: EXPERIMENTAL
Intervention: Conformal neutron/photon irradiation without neoadjuvant hormonal therapy
Number of subjects: 76
Study 8751396 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional erections pretreatment
Number of subjects: 76
Study 8751396 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfunctional erections pretreatment
Number of subjects: 76
Study 1596562 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-purity, pasteurized FVIII-vWF concentrate
Number of subjects: 10
Study 1596562 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-purity, dry-heated FVIII-vWF concentrate
Number of subjects: 10
Study 1596562 — intervention group
Group type: EXPERIMENTAL
Intervention: Solvent/detergent-treated FVIII-vWF concentrate
Number of subjects: 10
Study 1596562 — intervention group
Group type: EXPERIMENTAL
Intervention: High-purity solvent/detergent-treated FVIII-vWF concentrate
Number of subjects: 10
Study 1596562 — intervention group
Group type: EXPERIMENTAL
Intervention: Solvent/detergent-treated vWF concentrate (containing little FVIII)
Number of subjects: 10
Study 4070189 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive teaching emphasizing factual knowledge
Number of subjects: 1733
Study 4070189 — intervention group
Group type: EXPERIMENTAL
Intervention: Affective teaching stressing feelings, attitudes, and values
Number of subjects: 1733
Study 4070189 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed approach combining cognitive and affective features
Number of subjects: 1733
Study 4070189 — intervention group
Group type: EXPERIMENTAL
Intervention: All teaching groups
Number of subjects: 1733
Study 4070189 — intervention group
Group type: EXPERIMENTAL
Intervention: Affective and cognitive approaches
Number of subjects: 1733
Study 31995183 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-valent or 13-valent PCV
Number of subjects: 1754
Study 30844656 — intervention group
Group type: EXPERIMENTAL
Intervention: Sapylin (OK-432)
Number of subjects: 120
Study 30844656 — intervention group
Group type: COMPARATOR
Intervention: Control (no Sapylin)
Number of subjects: 120
Study 29902979 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% imiquimod cream, applied intravaginally three times a week for 16 weeks.
Number of subjects: 433
Study 29902979 — intervention group
Group type: COMPARATOR
Intervention: Large Loop Excision of the Transformation Zone (LLETZ) treatment, performed according to current guidelines.
Number of subjects: 433
Study 26841373 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intramuscular injection of 0.03 mg rhTSH
Number of subjects: 40
Study 26841373 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 40
Study 24417410 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory training
Number of subjects: 2832
Study 24417410 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasoning training
Number of subjects: 2832
Study 24417410 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed of processing training
Number of subjects: 2832
Study 24417410 — intervention group
Group type: COMPARATOR
Intervention: No-contact control group
Number of subjects: 2832
Study 23015069 — intervention group
Group type: EXPERIMENTAL
Intervention: PG refinement algorithm
Number of subjects: 310
Study 23015069 — intervention group
Group type: COMPARATOR
Intervention: PG algorithm
Number of subjects: 310
Study 23015069 — intervention group
Group type: COMPARATOR
Intervention: Fixed dose approach (3 mg/day)
Number of subjects: 310
Study 21050565 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block (CFNB)
Number of subjects: 32
Study 17655682 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin MELT (sublingual lyophilisate)
Number of subjects: 221
Study 17655682 — intervention group
Group type: COMPARATOR
Intervention: Tablet formulation of desmopressin
Number of subjects: 221
Study 16177537 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory based small angle x-ray scattering (SAXS) using the 'SAXSess' system
Number of subjects: 0
Study 12665498 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg micronized fenofibrate daily
Number of subjects: 418
Study 12665498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 418
Study 10372613 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scan
Number of subjects: 39
Study 10372613 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 39
Study 8647327 — intervention group
Group type: EXPERIMENTAL
Intervention: Developmental language disorder (phonologic‐syntactic)
Number of subjects: 0
Study 8647327 — intervention group
Group type: EXPERIMENTAL
Intervention: Developmental language disorder (semantic‐pragmatic)
Number of subjects: 0
Study 8647327 — intervention group
Group type: EXPERIMENTAL
Intervention: High-level autism
Number of subjects: 0
Study 8647327 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal children)
Number of subjects: 0
Study 1906160 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefprozil (30 mg/kg/day divided into two equal doses)
Number of subjects: 137
Study 1906160 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin clavulanate potassium (40 mg/kg/day divided into three equal doses)
Number of subjects: 137
Study 1906160 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefprozil
Number of subjects: 137
Study 1906160 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin clavulanate potassium
Number of subjects: 137
Study 6137601 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldose reductase inhibitor ('Sorbinil'‐‐Pfizer CP 45, 634)
Number of subjects: 11
Study 6137601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 29458919 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga meditation (YoMed)
Number of subjects: 16
Study 29458919 — intervention group
Group type: COMPARATOR
Intervention: Proprioceptive Training (PT)
Number of subjects: 16
Study 26782847 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid devices
Number of subjects: 20
Study 26782847 — intervention group
Group type: COMPARATOR
Intervention: Tooth-borne (TB) devices (Hyrax)
Number of subjects: 20
Study 23890072 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified method (group S)
Number of subjects: 39
Study 23890072 — intervention group
Group type: COMPARATOR
Intervention: Conventional method (group C)
Number of subjects: 39
Study 23052819 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponseti method for idiopathic clubfeet
Number of subjects: 101
Study 23052819 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponseti method for non-idiopathic clubfeet
Number of subjects: 101
Study 23052819 — intervention group
Group type: EXPERIMENTAL
Intervention: Abduction splint treatment compliance
Number of subjects: 101
Study 23052819 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse surgery
Number of subjects: 101
Study 20349354 — intervention group
Group type: EXPERIMENTAL
Intervention: High-impact exercise (HIE) for 12 months
Number of subjects: 91
Study 20349354 — intervention group
Group type: COMPARATOR
Intervention: Stretching exercise (SE) for 12 months
Number of subjects: 91
Study 18656044 — intervention group
Group type: EXPERIMENTAL
Intervention: Injury prevention program
Number of subjects: 262
Study 15816472 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant biofactor AOB (3x2 sachets of 3 g powder each for 3 months)
Number of subjects: 30
Study 15816472 — intervention group
Group type: COMPARATOR
Intervention: Placebo (herbal extract with no superoxide scavenging properties)
Number of subjects: 30
Study 15816472 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional antiviral treatment (pegylated interferon alpha and ribavirin) after 3 months
Number of subjects: 30
Study 12818407 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 122
Study 11328968 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural surfactant
Number of subjects: 21
Study 11328968 — intervention group
Group type: COMPARATOR
Intervention: Synthetic surfactant
Number of subjects: 21
Study 8692168 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis of randomized control trials
Number of subjects: 164
Study 1644539 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical drainage
Number of subjects: 97
Study 1644539 — intervention group
Group type: COMPARATOR
Intervention: No surgical drainage
Number of subjects: 97
Study 6369669 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose steroids with azathioprine
Number of subjects: 189
Study 6369669 — intervention group
Group type: COMPARATOR
Intervention: Low-dose steroids with azathioprine
Number of subjects: 189
Study 29943058 — intervention group
Group type: EXPERIMENTAL
Intervention: One-Anastomosis Gastric Bypass (OAGB)
Number of subjects: 600
Study 29943058 — intervention group
Group type: COMPARATOR
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 600
Study 29943058 — intervention group
Group type: COMPARATOR
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 600
Study 31234808 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional disinfection group
Number of subjects: 20
Study 31234808 — intervention group
Group type: COMPARATOR
Intervention: Non-disinfection group
Number of subjects: 20
Study 31234808 — intervention group
Group type: COMPARATOR
Intervention: Cesarean section group
Number of subjects: 20
Study 25367165 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual switch to iloperidone (n=240)
Number of subjects: 500
Study 25367165 — intervention group
Group type: COMPARATOR
Intervention: Immediate switch to iloperidone (n=260)
Number of subjects: 500
Study 25367165 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Gradual and Immediate switch)
Number of subjects: 500
Study 23365418 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular moderate-intensity exercise (three training sessions/week, 50-55 min/session)
Number of subjects: 510
Study 23365418 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular moderate-intensity exercise
Number of subjects: 510
Study 23365418 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 510
Study 22056450 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6% energy trans fatty acid (TFA) intake
Number of subjects: 0
Study 22056450 — intervention group
Group type: COMPARATOR
Intervention: Control (no TFA intake)
Number of subjects: 0
Study 19231581 — intervention group
Group type: EXPERIMENTAL
Intervention: HIFU ablation of the primary breast cancer prior to modified radical mastectomy (n = 23)
Number of subjects: 48
Study 19231581 — intervention group
Group type: COMPARATOR
Intervention: Control group with modified radical mastectomy only (n = 25)
Number of subjects: 48
Study 19231581 — intervention group
Group type: EXPERIMENTAL
Intervention: HIFU group (n = 23)
Number of subjects: 48
Study 19231581 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 25)
Number of subjects: 48
Study 16536341 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Prompt L‐Pop (APLP)
Number of subjects: 120
Study 16536341 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompt L‐Pop 2 (PLP)
Number of subjects: 120
Study 16536341 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond Multipurpose Plus (SMP)
Number of subjects: 120
Study 12626303 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast track protocol (group A)
Number of subjects: 100
Study 12626303 — intervention group
Group type: COMPARATOR
Intervention: Conventional anesthesia (group B)
Number of subjects: 100
Study 11011808 — intervention group
Group type: EXPERIMENTAL
Intervention: tinzaparin
Number of subjects: 499
Study 11011808 — intervention group
Group type: EXPERIMENTAL
Intervention: enoxaparin
Number of subjects: 499
Study 9295822 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunonutritional diet (n = 77)
Number of subjects: 154
Study 9295822 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric and isonitrogenous placebo diet (n = 77)
Number of subjects: 154
Study 7801580 — intervention group
Group type: EXPERIMENTAL
Intervention: CA125 measurements
Number of subjects: 131
Study 7801580 — intervention group
Group type: COMPARATOR
Intervention: CEA measurements
Number of subjects: 131
Study 3521518 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bacitracin
Number of subjects: 24
Study 3521518 — intervention group
Group type: COMPARATOR
Intervention: Oral vancomycin
Number of subjects: 24
Study 28395549 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 1944
Study 28395549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1944
Study 26379068 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 Gag- and Nef-transfected DCs (vaccine)
Number of subjects: 15
Study 26379068 — intervention group
Group type: COMPARATOR
Intervention: Mock-transfected DCs (placebo)
Number of subjects: 15
Study 25486673 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based physical activity program (Philips DirectLife) for 12 weeks
Number of subjects: 235
Study 25486673 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in minutes spent in moderate-to-vigorous activity
Number of subjects: 235
Study 22936148 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric test with air at 50ºC
Number of subjects: 40
Study 22936148 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric test with air at 24ºC
Number of subjects: 40
Study 22936148 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric test with water at 44ºC
Number of subjects: 40
Study 22936148 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric test with water at 30ºC
Number of subjects: 40
Study 21275332 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy (MT) sessions multiple times per week
Number of subjects: 61
Study 18162944 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal conjugate vaccine
Number of subjects: 0
Study 16168533 — intervention group
Group type: EXPERIMENTAL
Intervention: Unexpected fast impact (10.0m/s2)
Number of subjects: 30
Study 16168533 — intervention group
Group type: EXPERIMENTAL
Intervention: Unexpected slow impact (4.5m/s2)
Number of subjects: 30
Study 16168533 — intervention group
Group type: EXPERIMENTAL
Intervention: All impacts
Number of subjects: 30
Study 12941198 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent advances in biologic response modifier therapy
Number of subjects: 0
Study 12941198 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoreductive nephrectomy
Number of subjects: 0
Study 10230954 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrinone (loading dose of 2 mg/kg, maintenance infusion of 7.5 microg/kg/min)
Number of subjects: 35
Study 10230954 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrinone
Number of subjects: 35
Study 10230954 — intervention group
Group type: COMPARATOR
Intervention: Dopamine and nitroglycerin (dopamine 5 microg/kg/min, nitroglycerin 1 microg/kg/min)
Number of subjects: 35
Study 8674002 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line hormonal therapy with megestrol acetate or fadrozole
Number of subjects: 300
Study 1688356 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambroxol (1 g/day intravenously for 6 consecutive days)
Number of subjects: 252
Study 1688356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study 7017343 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion at a rate of 0.33 mU/kg/min
Number of subjects: 5
Study 7017343 — intervention group
Group type: COMPARATOR
Intervention: No insulin infusion (control)
Number of subjects: 5
Study 31553457 — intervention group
Group type: EXPERIMENTAL
Intervention: NKTR-181 400 mg
Number of subjects: 71
Study 31553457 — intervention group
Group type: EXPERIMENTAL
Intervention: NKTR-181 600 mg
Number of subjects: 71
Study 31553457 — intervention group
Group type: EXPERIMENTAL
Intervention: NKTR-181 400 mg and 600 mg
Number of subjects: 71
Study 31553457 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone 40 mg
Number of subjects: 71
Study 31553457 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone 60 mg
Number of subjects: 71
Study 31553457 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone
Number of subjects: 71
Study 30813155 — intervention group
Group type: EXPERIMENTAL
Intervention: Trigger point dry needling
Number of subjects: 160
Study 30813155 — intervention group
Group type: COMPARATOR
Intervention: Sham dry needling
Number of subjects: 160
Study 29265090 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolpersione injection and oral formulations combined with NSAID
Number of subjects: 239